Business Context and Reporting Period
Company: CVS Caremark Corporation (formerly CVS Corporation)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 29, 2007 (52 weeks)
Overview: CVS Caremark is the largest provider of prescriptions and related healthcare services in the United States, filling or managing over one billion prescriptions annually. The company operates two primary segments: Retail Pharmacy (6,245 stores as of period end) and Pharmacy Services (PBM, mail order, and specialty pharmacy). A defining event for the period was the completion of the merger with Caremark Rx, Inc. on March 22, 2007, creating a fully integrated pharmacy services company.
Key Financial Metrics
| Metric (in millions, except per share) | 2007 | 2006 |
|---|---|---|
| Net Revenues | $76,329.5 | $43,821.4 |
| Gross Profit | $16,107.7 | $11,742.2 |
| Operating Profit | $4,793.3 | $2,441.6 |
| Net Earnings | $2,637.0 | $1,368.9 |
| Diluted EPS | $1.92 | $1.60 |
| Total Assets | $54,721.9 | $20,574.1 |
| Long-term Debt | $8,349.7 | $2,870.4 |
| Total Shareholders' Equity | $31,321.9 | $9,917.6 |
Revenue Composition (2007): Prescription drugs accounted for 68% of net revenues, followed by general merchandise and other (15%), over-the-counter and personal care (13%), and beauty/cosmetics (4%).
Liquidity and Capital: The company funds growth through cash flow from operations, sale-leaseback transactions, commercial paper, and long-term borrowings. Managed care and third-party insurance programs represented approximately 98% of pharmacy revenues in 2007, typically settling in less than 30 days.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by approximately 74% year-over-year, driven primarily by the inclusion of Caremark's revenues following the March 2007 merger.
- Profitability: Operating profit nearly doubled from $2.44 billion to $4.79 billion, and net earnings increased by 93% to $2.64 billion.
- Balance Sheet Expansion: Total assets more than doubled to $54.7 billion, and long-term debt increased significantly to $8.35 billion to finance the merger and operations.
- Store Count: The retail store base grew to 6,245 stores (including 462 MinuteClinics), with 139 new stores opened and 136 relocated in 2007.
- Accounting Firm Change: KPMG LLP was dismissed as the principal accountant on September 26, 2007, and replaced by Ernst & Young LLP. No disagreements were reported regarding accounting principles or practices.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: Management expects the Caremark Merger to yield significant synergies through purchasing scale and operating efficiencies. The company anticipates incremental revenue opportunities from new programs, including prescription compliance, disease management, and flexible fulfillment options. For 2008, the company expects to open between 300 and 325 new or relocated stores.
Key Risks:
- Regulatory Environment: The business is subject to extensive federal and state regulations regarding Medicare Part D, Medicaid reimbursement, anti-remuneration laws, and PBM activities. Changes in reimbursement formulas (e.g., Medicaid generic drug reimbursement) could adversely affect profitability.
- Merger Integration: There is a risk of failing to realize anticipated cost savings and strategic benefits from the Caremark Merger.
- Competition: The industry is highly competitive with pressure on reimbursement rates and gross margins, particularly in the PBM sector.
- Legal Proceedings: The company faces various litigation matters, including a multi-state consumer protection settlement (agreed to in Feb 2008 for approx. $41 million in payments plus costs), antitrust lawsuits regarding pharmacy networks, and qui tam lawsuits regarding government claims processing.
Unusual Items: The financial data includes the impact of the Caremark Merger. The company also engaged in significant share repurchase activity, including a $5.0 billion program and accelerated share repurchase agreements totaling $4.8 billion in 2007.
Investor Verification Checklist
- Merger Synergies: Verify the actual realization of cost synergies and revenue growth attributed to the Caremark integration in subsequent quarters.
- Regulatory Impact: Monitor developments in Medicaid reimbursement rules (specifically the AMP Rule and generic drug pricing) and their effect on gross margins.
- Legal Settlements: Track the final court approval and financial impact of the multi-state consumer protection settlement and ongoing antitrust litigation.
- Debt Servicing: Assess the company's ability to service the increased long-term debt load ($8.35 billion) amidst potential margin pressure.
- Medicare Part D Performance: Evaluate the performance of the SilverScript subsidiary and the impact of increased risk-sharing thresholds for 2008.